(BMY) Bristol-Myers Squibb - Overview
Stock: Oncology, Immunology, Hematology, Cardiovascular, Neurology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.98% |
| Yield on Cost 5y | 5.04% |
| Yield CAGR 5y | 13.97% |
| Payout Consistency | 92.6% |
| Payout Ratio | 50.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.0% |
| Relative Tail Risk | -9.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | 1.25 |
| Character TTM | |
|---|---|
| Beta | 0.322 |
| Beta Downside | 0.369 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.43% |
| CAGR/Max DD | -0.01 |
Description: BMY Bristol-Myers Squibb January 27, 2026
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes prescription medicines across oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. Its flagship products include Eliquis (anticoagulant), Opdivo (PD-1 checkpoint inhibitor), Revlimid (multiple myeloma), and newer launches such as Krazati (KRAS G12C NSCLC) and Opdualag (melanoma).
In the most recent quarter (Q2 2024), BMY reported revenue of **$13.2 billion**, up **7 % YoY**, driven primarily by oncology sales (+9 %) and the continued growth of Eliquis (+5 %). Adjusted earnings per share were **$2.30**, and the company spent **$6.2 billion** on R&D, representing roughly **47 %** of net sales. As of the end of June 2024, BMY’s net debt stood at **$30 billion**, while its cash-equivalent balance was **$5.5 billion**, giving a net-debt-to-EBITDA ratio of about **2.3×**, indicating moderate leverage relative to peers.
Key macro- and sector-level drivers for BMY include: (1) an aging U.S. and global population that sustains demand for chronic-disease therapies such as anticoagulants and immunomodulators; (2) the oncology market’s projected **CAGR of ~6 % through 2030**, which benefits BMY’s expanding pipeline of checkpoint inhibitors and KRAS-targeted agents; and (3) pricing pressure from biosimilars and payer reforms, which could compress margins unless offset by higher-value specialty products. The company’s pipeline contains several late-stage candidates (e.g., a next-generation CAR-T therapy and a novel anti-fibrotic agent) that could diversify revenue streams but also introduce execution risk.
For a deeper, data-driven assessment of BMY’s valuation dynamics, consider exploring the detailed analyst models on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 6.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 1.06 > 1.0 |
| NWC/Revenue: 15.60% < 20% (prev 11.46%; Δ 4.14% < -1%) |
| CFO/TA 0.17 > 3% & CFO 16.62b > Net Income 6.04b |
| Net Debt (35.31b) to EBITDA (14.90b): 2.37 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.34% < -2% |
| Gross Margin: 65.83% > 18% (prev 0.56%; Δ 6527 % > 0.5%) |
| Asset Turnover: 50.41% > 50% (prev 50.64%; Δ -0.23% > 0%) |
| Interest Coverage Ratio: 5.11 > 6 (EBITDA TTM 14.90b / Interest Expense TTM 1.96b) |
Altman Z'' 2.00
| A: 0.08 (Total Current Assets 35.63b - Total Current Liabilities 28.14b) / Total Assets 96.89b |
| B: 0.18 (Retained Earnings 17.09b / Total Assets 96.89b) |
| C: 0.10 (EBIT TTM 9.99b / Avg Total Assets 95.28b) |
| D: 0.20 (Book Value of Equity 15.87b / Total Liabilities 78.29b) |
| Altman-Z'' Score: 2.00 = BBB |
Beneish M -3.35
| DSRI: 0.97 (Receivables 14.62b/14.89b, Revenue 48.03b/47.44b) |
| GMI: 0.85 (GM 65.83% / 55.87%) |
| AQI: 0.91 (AQ_t 0.56 / AQ_t-1 0.61) |
| SGI: 1.01 (Revenue 48.03b / 47.44b) |
| TATA: -0.11 (NI 6.04b - CFO 16.62b) / TA 96.89b) |
| Beneish M-Score: -3.35 (Cap -4..+1) = AA |
What is the price of BMY shares?
Over the past week, the price has changed by +12.61%, over one month by +13.91%, over three months by +34.51% and over the past year by +13.41%.
Is BMY a buy, sell or hold?
- StrongBuy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 58 | -6.4% |
| Analysts Target Price | 58 | -6.4% |
| ValueRay Target Price | 70.9 | 14.3% |
BMY Fundamental Data Overview February 03, 2026
P/E Forward = 9.2251
P/S = 2.3687
P/B = 6.0408
P/EG = 2.2562
Revenue TTM = 48.03b USD
EBIT TTM = 9.99b USD
EBITDA TTM = 14.90b USD
Long Term Debt = 44.47b USD (from longTermDebt, last quarter)
Short Term Debt = 4.72b USD (from shortTermDebt, last quarter)
Debt = 51.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.31b USD (from netDebt column, last quarter)
Enterprise Value = 149.09b USD (113.78b + Debt 51.04b - CCE 15.73b)
Interest Coverage Ratio = 5.11 (Ebit TTM 9.99b / Interest Expense TTM 1.96b)
EV/FCF = 9.74x (Enterprise Value 149.09b / FCF TTM 15.30b)
FCF Yield = 10.26% (FCF TTM 15.30b / Enterprise Value 149.09b)
FCF Margin = 31.86% (FCF TTM 15.30b / Revenue TTM 48.03b)
Net Margin = 12.57% (Net Income TTM 6.04b / Revenue TTM 48.03b)
Gross Margin = 65.83% ((Revenue TTM 48.03b - Cost of Revenue TTM 16.41b) / Revenue TTM)
Gross Margin QoQ = 71.89% (prev 65.78%)
Tobins Q-Ratio = 1.54 (Enterprise Value 149.09b / Total Assets 96.89b)
Interest Expense / Debt = 0.94% (Interest Expense 480.0m / Debt 51.04b)
Taxrate = 29.51% (919.0m / 3.11b)
NOPAT = 7.04b (EBIT 9.99b * (1 - 29.51%))
Current Ratio = 1.27 (Total Current Assets 35.63b / Total Current Liabilities 28.14b)
Debt / Equity = 2.75 (Debt 51.04b / totalStockholderEquity, last quarter 18.55b)
Debt / EBITDA = 2.37 (Net Debt 35.31b / EBITDA 14.90b)
Debt / FCF = 2.31 (Net Debt 35.31b / FCF TTM 15.30b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.34% (Net Income 6.04b / Total Assets 96.89b)
RoE = 34.65% (Net Income TTM 6.04b / Total Stockholder Equity 17.43b)
RoCE = 16.14% (EBIT 9.99b / Capital Employed (Equity 17.43b + L.T.Debt 44.47b))
RoIC = 10.54% (NOPAT 7.04b / Invested Capital 66.81b)
WACC = 5.11% (E(113.78b)/V(164.82b) * Re(7.10%) + D(51.04b)/V(164.82b) * Rd(0.94%) * (1-Tc(0.30)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.12%
[DCF Debug] Terminal Value 87.00% ; FCFF base≈14.70b ; Y1≈15.76b ; Y5≈19.16b
Fair Price DCF = 261.3 (EV 567.21b - Net Debt 35.31b = Equity 531.89b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -23.61 | EPS CAGR: -9.43% | SUE: -4.0 | # QB: 0
Revenue Correlation: 37.61 | Revenue CAGR: 0.52% | SUE: 1.47 | # QB: 8
EPS next Quarter (2026-03-31): EPS=1.42 | Chg30d=-0.020 | Revisions Net=+1 | Analysts=11
EPS next Year (2026-12-31): EPS=6.01 | Chg30d=+0.015 | Revisions Net=+3 | Growth EPS=-2.0% | Growth Revenue=-7.9%